A Mobile-Based Screening System for Data Analyses of Early Dementia Traits Detection

An update on mobile applications collecting data among subjects with or at risk of Alzheimer's disease

Smart mobile phone use is increasing worldwide, as is the ability of mobile devices to monitor daily routines, behaviors, and even cognitive changes. There is a growing opportunity for users to share the data collected with their medical providers which may serve as an accessible cognitive impairment screening tool. Data logged or tracked in an app and analyzed with machine learning (ML) could identify subtle cognitive changes and lead to more timely diagnoses on an individual and population level. This review comments on existing evidence of mobile device applications designed to passively and/or actively collect data on cognition relevant for early detection and diagnosis of Alzheimer's disease (AD). The PubMed database was searched to identify existing literature on apps related to dementia and cognitive health data collection. The initial search deadline was December 1, 2022. Additional literature published in 2023 was accounted for with a follow-up search prior to publication. Criteria for inclusion was limited to articles in English which referenced data collection via mobile app from adults 50+ concerned, at risk of, or diagnosed with AD dementia. We identified relevant literature (n = 25) which fit our criteria. Many publications were excluded because they focused on apps which fail to collect data and simply provide users with cognitive health information. We found that although data collecting cognition-related apps have existed for years, the use of these apps as screening tools remains underdeveloped; however, it may serve as proof of concept and feasibility as there is much supporting evidence on their predictive utility. Concerns about the validity of mobile apps for cognitive screening and privacy issues remain prevalent. Mobile applications and use of ML is widely considered a financially and socially viable method of compiling symptomatic data but currently this large potential dataset, screening tool, and research resource is still largely untapped.

Ethical issues when using digital biomarkers and artificial intelligence for the early detection of dementia

Dementia poses a growing challenge for health services but remains stigmatized and under-recognized. Digital technologies to aid the earlier detection of dementia are approaching market. These include traditional cognitive screening tools presented on mobile devices, smartphone native applications, passive data collection from wearable, in-home and in-car sensors, as well as machine learning techniques applied to clinic and imaging data. It has been suggested that earlier detection and diagnosis may help patients plan for their future, achieve a better quality of life, and access clinical trials and possible future disease modifying treatments. In this review, we explore whether digital tools for the early detection of dementia can or should be deployed, by assessing them against the principles of ethical screening programs. We conclude that while the importance of dementia as a health problem is unquestionable, significant challenges remain. There is no available treatment which improves the prognosis of diagnosed disease. Progression from early-stage disease to dementia is neither given nor currently predictable. Available technologies are generally not both minimally invasive and highly accurate. Digital deployment risks exacerbating health inequalities due to biased training data and inequity in digital access. Finally, the acceptability of early dementia detection is not established, and resources would be needed to ensure follow-up and support for those flagged by any new system. We conclude that early dementia detection deployed at scale via digital technologies does not meet standards for a screening program and we offer recommendations for moving toward an ethical mode of implementation. This article is categorized under:Application Areas > Health CareCommercial, Legal, and Ethical Issues > Ethical ConsiderationsTechnologies > Artificial Intelligence.

The current state of artificial intelligence-augmented digitized neurocognitive screening test

The cognitive screening test is a brief cognitive examination that could be easily performed in a clinical setting. However, one of the main drawbacks of this test was that only a paper-based version was available, which restricts the test to be manually administered and graded by medical personnel at the health centers. The main solution to these problems was to develop a potential remote assessment for screening individuals with cognitive impairment. Currently, multiple studies have been adopting artificial intelligence (AI) technology into these tests, evolving the conventional paper-based neurocognitive test into a digitized AI-assisted neurocognitive test. These studies provided credible evidence of the potential of AI-augmented cognitive screening tests to be better and provided the framework for future studies to further improve the implementation of AI technology in the cognitive screening test. The objective of this review article is to discuss different types of AI used in digitized cognitive screening tests and their advantages and disadvantages.

Digital healthcare for dementia and cognitive impairment: A scoping review

BACKGROUND

Cognitive disorders, such as Alzheimer's disease, are a global health problem. Digital healthcare technology is an innovative management tool for delaying the progression of dementia and mild cognitive impairment. Thanks to digital technology, the possibility of safe and effective care for patients at home and in the community is increasing, even in situations that threaten the continuity of care, such as the COVID-19 pandemic. However, it is difficult to select appropriate technology and alternatives due to the lack of comprehensive reviews on the types and characteristics of digital technology for cognitive impairment, including their effects and limitations.

OBJECTIVE

This study aims to identify the types of digital healthcare technology for dementia and mild cognitive impairment and comprehensively examine how its outcome measures were constructed in line with each technology's purpose.

METHODS

According to the Preferred Reporting Items for Systematic reviews and Meta-Analysis extension for Scoping Reviews guidelines, a literature search was conducted in August 2021 using Medline (Ovid), EMBASE, and Cochrane library. The search terms were constructed based on Population-Concept-Context mnemonic: 'dementia', 'cognitive impairment', and 'cognitive decline'; digital healthcare technology, such as big data, artificial intelligence, virtual reality, robots, applications, and so on; and the outcomes of digital technology, such as accuracy of diagnosis and physical, mental, and social health. After grasping overall research trends, the literature was classified and analysed in terms of the type of service users and technology.

RESULTS

In total, 135 articles were selected. Since 2015, an increase in literature has been observed, and various digital healthcare technologies were identified. For people with mild cognitive impairment, technology for predicting and diagnosing the onset of dementia was studied, and for people with dementia, intervention technology to prevent the deterioration of health and induce significant improvement was considered. Regarding caregivers, many studies were conducted on monitoring and daily living assistive technologies that reduce the burden of care. However, problems such as data collection, storage, safety, and the digital divide persisted at different intensities for each technology type.

CONCLUSIONS

This study revealed that appropriate technology options and considerations may differ depending on the characteristics of users. It also emphasises the role of humans in designing and managing technology to apply digital healthcare technology more effectively.

A Deep Neural Network-Based Model for Screening Autism Spectrum Disorder Using the Quantitative Checklist for Autism in Toddlers (QCHAT)

Autism spectrum disorder (ASD) is an abnormal condition of brain development characterized by impaired cognitive ability, speech and human interactions, in addition to a set of repetitive and stereotyped patterns of behaviours. Although no cure for autism exists, early medical intervention can improve the associated symptoms and quality of life. Several manually executed screening tools help to identify the ASD-related behavioural traits in the children that assists the specialist in diagnosing the disease accurately. The quantitative checklist for autism in toddlers (QCHAT) is one of the efficient screening tools used worldwide for ASD screening. ASD diagnosis requires many different manually administered procedures; hence long delay is encountered in getting final results. In recent years, deep neural network (DNN) popularity has been immensely increasing due to its supremacy in solving complex problems. The objective of this research is to apply algorithms, based on the deep neural network (DNN) to identify patients with ASD from the QCHAT datasets. We have used two datasets, the QCHAT and QCHAT-10, in our study. The results obtained show that related to contemporary techniques, the proposed method brings better performance.

Brain Asymmetry Detection and Machine Learning Classification for Diagnosis of Early Dementia

Early identification of degenerative processes in the human brain is considered essential for providing proper care and treatment. This may involve detecting structural and functional cerebral changes such as changes in the degree of asymmetry between the left and right hemispheres. Changes can be detected by computational algorithms and used for the early diagnosis of dementia and its stages (amnestic early mild cognitive impairment (EMCI), Alzheimer’s Disease (AD)), and can help to monitor the progress of the disease. In this vein, the paper proposes a data processing pipeline that can be implemented on commodity hardware. It uses features of brain asymmetries, extracted from MRI of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, for the analysis of structural changes, and machine learning classification of the pathology. The experiments provide promising results, distinguishing between subjects with normal cognition (NC) and patients with early or progressive dementia. Supervised machine learning algorithms and convolutional neural networks tested are reaching an accuracy of 92.5% and 75.0% for NC vs. EMCI, and 93.0% and 90.5% for NC vs. AD, respectively. The proposed pipeline offers a promising low-cost alternative for the classification of dementia and can be potentially useful to other brain degenerative disorders that are accompanied by changes in the brain asymmetries.

Dementia medical screening using mobile applications: A systematic review with a new mapping model

Early detection is the key to successfully tackling dementia, a neurocognitive condition common among the elderly. Therefore, screening using technological platforms such as mobile applications (apps) may provide an important opportunity to speed up the diagnosis process and improve accessibility. Due to the lack of research into dementia diagnosis and screening tools based on mobile apps, this systematic review aims to identify the available mobile-based dementia and mild cognitive impairment (MCI) apps using specific inclusion and exclusion criteria. More importantly, we critically analyse these tools in terms of their comprehensiveness, validity, performance, and the use of artificial intelligence (AI) techniques. The research findings suggest diagnosticians in a clinical setting use dementia screening apps such as ALZ and CognitiveExams since they cover most of the domains for the diagnosis of neurocognitive disorders. Further, apps such as Cognity and ACE-Mobile have great potential as they use machine learning (ML) and AI techniques, thus improving the accuracy of the outcome and the efficiency of the screening process. Lastly, there was overlapping among the dementia screening apps in terms of activities and questions they contain therefore mapping these apps to the designated cognitive domains is a challenging task, which has been done in this research.

Data Imbalance in Autism Pre-Diagnosis Classification Systems: An Experimental Study

Machine learning (ML) is a branch of computer science that is rapidly gaining popularity within the healthcare arena due to its ability to explore large datasets to discover useful patterns that can be interepreted for decision-making and prediction. ML techniques are used for the analysis of clinical parameters and their combinations for prognosis, therapy planning and support and patient management and wellbeing. In this research, we investigate a crucial problem associated with medical applications such as autism spectrum disorder (ASD) data imbalances in which cases are far more than just controls in the dataset. In autism diagnosis data, the number of possible instances is linked with one class, i.e. the no ASD is larger than the ASD, and this may cause performance issues such as models favouring the majority class and undermining the minority class. This research experimentally measures the impact of class imbalance issue on the performance of different classifiers on real autism datasets when various data imbalance approaches are utilised in the pre-processing phase. We employ oversampling techniques, such as Synthetic Minority Oversampling (SMOTE), and undersampling with different classifiers including Naive Bayes, RIPPER, C4.5 and Random Forest to measure the impact of these on the performance of the models derived in terms of area under curve and other metrics. Results pinpoint that oversampling techniques are superior to undersampling techniques, at least for the toddlers’ autism dataset that we consider, and suggest that further work should look at incorporating sampling techniques with feature selection to generate models that do not overfit the dataset.